ID   GALM_HUMAN              Reviewed;         342 AA.
AC   Q96C23; Q53RY1; Q8NIA2; V9HWA8;
DT   10-MAY-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   03-AUG-2022, entry version 161.
DE   RecName: Full=Galactose mutarotase {ECO:0000303|PubMed:12753898, ECO:0000303|PubMed:15026423};
DE            EC=5.1.3.3 {ECO:0000269|PubMed:12753898};
DE   AltName: Full=Aldose 1-epimerase {ECO:0000303|PubMed:12753898};
GN   Name=GALM {ECO:0000312|HGNC:HGNC:24063}; ORFNames=BLOCK25;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Gorry M.C., Zhang Y., Marks J.J., Suppes B., Hart P.S., Cortelli J.R.,
RA   Pallos D., Hart T.C.;
RT   "Physical/genetic map of the 2p22-2p21 region on chromosome 2.";
RL   Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Li J.Y., Wang H.Y., Liu F.J., Liu J.;
RL   Submitted (JUN-2008) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, MUTAGENESIS OF HIS-107; HIS-176 AND GLU-307, CATALYTIC ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND SUBSTRATE SPECIFICITY.
RX   PubMed=12753898; DOI=10.1016/s0014-5793(03)00364-8;
RA   Timson D.J., Reece R.J.;
RT   "Identification and characterisation of human aldose 1-epimerase.";
RL   FEBS Lett. 543:21-24(2003).
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12] {ECO:0007744|PDB:1SNZ, ECO:0007744|PDB:1SO0}
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEX WITH BETA-D-GALACTOSE,
RP   ACTIVE SITE, AND SUBUNIT.
RX   PubMed=15026423; DOI=10.1074/jbc.m402347200;
RA   Thoden J.B., Timson D.J., Reece R.J., Holden H.M.;
RT   "Molecular structure of human galactose mutarotase.";
RL   J. Biol. Chem. 279:23431-23437(2004).
RN   [13]
RP   VARIANTS GALAC4 82-ARG--ALA-342 DEL; ARG-142; GLY-267 AND 311-TRP--ALA-342
RP   DEL, CHARACTERIZATION OF VARIANTS GALAC4 82-ARG--ALA-342 DEL; ARG-142;
RP   GLY-267 AND 311-TRP--ALA-342 DEL, FUNCTION, AND INVOLVEMENT IN GALAC4.
RX   PubMed=30451973; DOI=10.1038/s41436-018-0340-x;
RA   Wada Y., Kikuchi A., Arai-Ichinoi N., Sakamoto O., Takezawa Y., Iwasawa S.,
RA   Niihori T., Nyuzuki H., Nakajima Y., Ogawa E., Ishige M., Hirai H.,
RA   Sasai H., Fujiki R., Shirota M., Funayama R., Yamamoto M., Ito T.,
RA   Ohara O., Nakayama K., Aoki Y., Koshiba S., Fukao T., Kure S.;
RT   "Biallelic GALM pathogenic variants cause a novel type of galactosemia.";
RL   Genet. Med. 21:1286-1294(2019).
CC   -!- FUNCTION: Mutarotase that catalyzes the interconversion of beta-D-
CC       galactose and alpha-D-galactose during galactose metabolism
CC       (PubMed:12753898). Beta-D-galactose is metabolized in the liver into
CC       glucose 1-phosphate, the primary metabolic fuel, by the action of four
CC       enzymes that constitute the Leloir pathway: GALM, GALK1
CC       (galactokinase), GALT (galactose-1-phosphate uridylyltransferase) and
CC       GALE (UDP-galactose-4'-epimerase) (PubMed:30451973). Involved in the
CC       maintenance of the equilibrium between the beta- and alpha-anomers of
CC       galactose, therefore ensuring a sufficient supply of the alpha-anomer
CC       for GALK1 (PubMed:12753898). Also active on D-glucose although shows a
CC       preference for galactose over glucose (PubMed:12753898).
CC       {ECO:0000269|PubMed:12753898, ECO:0000269|PubMed:30451973}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=alpha-D-galactose = beta-D-galactose; Xref=Rhea:RHEA:28675,
CC         ChEBI:CHEBI:27667, ChEBI:CHEBI:28061; EC=5.1.3.3;
CC         Evidence={ECO:0000269|PubMed:12753898};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:28677;
CC         Evidence={ECO:0000305|PubMed:12753898};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=alpha-D-glucose = beta-D-glucose; Xref=Rhea:RHEA:10264,
CC         ChEBI:CHEBI:15903, ChEBI:CHEBI:17925; EC=5.1.3.3;
CC         Evidence={ECO:0000269|PubMed:12753898};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=37 mM for galactose (at 20 degrees Celsius)
CC         {ECO:0000269|PubMed:12753898};
CC         KM=54 mM for glucose (at 20 degrees Celsius)
CC         {ECO:0000269|PubMed:12753898};
CC         Note=kcat is 12000 sec(-1) with galactose as substrate
CC         (PubMed:12753898). kcat is 4900 sec(-1) with glucose as substrate
CC         (PubMed:12753898). {ECO:0000269|PubMed:12753898};
CC   -!- PATHWAY: Carbohydrate metabolism; hexose metabolism.
CC       {ECO:0000305|PubMed:12753898}.
CC   -!- PATHWAY: Carbohydrate metabolism; galactose metabolism.
CC       {ECO:0000305|PubMed:12753898}.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:12753898,
CC       ECO:0000269|PubMed:15026423}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305}.
CC   -!- DISEASE: Galactosemia 4 (GALAC4) [MIM:618881]: A form of galactosemia,
CC       an inborn error of galactose metabolism typically manifesting in the
CC       neonatal period, after ingestion of galactose, with jaundice,
CC       hepatosplenomegaly, hepatocellular insufficiency, food intolerance,
CC       hypoglycemia, renal tubular dysfunction, muscle hypotonia, sepsis and
CC       cataract. GALAC4 inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:30451973}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the aldose epimerase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAL62475.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY064382; AAL62475.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AY064381; AAL62475.1; JOINED; Genomic_DNA.
DR   EMBL; AY064379; AAL62475.1; JOINED; Genomic_DNA.
DR   EMBL; AY064380; AAL62475.1; JOINED; Genomic_DNA.
DR   EMBL; AY064378; AAL62475.1; JOINED; Genomic_DNA.
DR   EMBL; AY064385; AAL62476.1; -; Genomic_DNA.
DR   EMBL; AY064378; AAL62476.1; JOINED; Genomic_DNA.
DR   EMBL; AY064380; AAL62476.1; JOINED; Genomic_DNA.
DR   EMBL; AY064379; AAL62476.1; JOINED; Genomic_DNA.
DR   EMBL; AY064381; AAL62476.1; JOINED; Genomic_DNA.
DR   EMBL; AY064384; AAL62476.1; JOINED; Genomic_DNA.
DR   EMBL; AY064383; AAL62476.1; JOINED; Genomic_DNA.
DR   EMBL; EU794611; ACJ13665.1; -; mRNA.
DR   EMBL; AK291489; BAF84178.1; -; mRNA.
DR   EMBL; AC074366; AAX93101.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00367.1; -; Genomic_DNA.
DR   EMBL; BC014916; AAH14916.1; -; mRNA.
DR   EMBL; BC019263; AAH19263.1; -; mRNA.
DR   CCDS; CCDS1797.1; -.
DR   RefSeq; NP_620156.1; NM_138801.2.
DR   RefSeq; XP_011530842.1; XM_011532540.1.
DR   PDB; 1SNZ; X-ray; 2.20 A; A/B=1-342.
DR   PDB; 1SO0; X-ray; 2.30 A; A/B/C/D=1-342.
DR   PDBsum; 1SNZ; -.
DR   PDBsum; 1SO0; -.
DR   AlphaFoldDB; Q96C23; -.
DR   SMR; Q96C23; -.
DR   BioGRID; 126244; 20.
DR   IntAct; Q96C23; 3.
DR   STRING; 9606.ENSP00000272252; -.
DR   iPTMnet; Q96C23; -.
DR   PhosphoSitePlus; Q96C23; -.
DR   BioMuta; GALM; -.
DR   DMDM; 67463772; -.
DR   EPD; Q96C23; -.
DR   jPOST; Q96C23; -.
DR   MassIVE; Q96C23; -.
DR   MaxQB; Q96C23; -.
DR   PaxDb; Q96C23; -.
DR   PeptideAtlas; Q96C23; -.
DR   PRIDE; Q96C23; -.
DR   ProteomicsDB; 76151; -.
DR   Antibodypedia; 29513; 223 antibodies from 26 providers.
DR   DNASU; 130589; -.
DR   Ensembl; ENST00000272252.10; ENSP00000272252.5; ENSG00000143891.17.
DR   GeneID; 130589; -.
DR   KEGG; hsa:130589; -.
DR   MANE-Select; ENST00000272252.10; ENSP00000272252.5; NM_138801.3; NP_620156.1.
DR   UCSC; uc002rqy.4; human.
DR   CTD; 130589; -.
DR   DisGeNET; 130589; -.
DR   GeneCards; GALM; -.
DR   HGNC; HGNC:24063; GALM.
DR   HPA; ENSG00000143891; Tissue enhanced (adrenal gland, kidney).
DR   MalaCards; GALM; -.
DR   MIM; 137030; gene.
DR   MIM; 618881; phenotype.
DR   neXtProt; NX_Q96C23; -.
DR   OpenTargets; ENSG00000143891; -.
DR   Orphanet; 570422; Galactose mutarotase deficiency.
DR   PharmGKB; PA134980075; -.
DR   VEuPathDB; HostDB:ENSG00000143891; -.
DR   eggNOG; KOG1604; Eukaryota.
DR   GeneTree; ENSGT00510000047589; -.
DR   HOGENOM; CLU_031753_2_0_1; -.
DR   InParanoid; Q96C23; -.
DR   OMA; ATWLSCK; -.
DR   OrthoDB; 978899at2759; -.
DR   PhylomeDB; Q96C23; -.
DR   TreeFam; TF324207; -.
DR   BioCyc; MetaCyc:HS07125-MON; -.
DR   BRENDA; 5.1.3.3; 2681.
DR   PathwayCommons; Q96C23; -.
DR   SABIO-RK; Q96C23; -.
DR   SignaLink; Q96C23; -.
DR   UniPathway; UPA00214; -.
DR   UniPathway; UPA00242; -.
DR   BioGRID-ORCS; 130589; 12 hits in 1078 CRISPR screens.
DR   ChiTaRS; GALM; human.
DR   EvolutionaryTrace; Q96C23; -.
DR   GeneWiki; Galactose_mutarotase; -.
DR   GenomeRNAi; 130589; -.
DR   Pharos; Q96C23; Tbio.
DR   PRO; PR:Q96C23; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q96C23; protein.
DR   Bgee; ENSG00000143891; Expressed in kidney epithelium and 187 other tissues.
DR   ExpressionAtlas; Q96C23; baseline and differential.
DR   Genevisible; Q96C23; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0004034; F:aldose 1-epimerase activity; IDA:UniProtKB.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:InterPro.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IDA:MGI.
DR   GO; GO:0033499; P:galactose catabolic process via UDP-galactose; IDA:MGI.
DR   GO; GO:0006012; P:galactose metabolic process; IDA:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IDA:UniProtKB.
DR   Gene3D; 2.70.98.10; -; 1.
DR   InterPro; IPR018052; Ald1_epimerase_CS.
DR   InterPro; IPR015443; Aldose_1-epimerase.
DR   InterPro; IPR008183; Aldose_1/G6P_1-epimerase.
DR   InterPro; IPR011013; Gal_mutarotase_sf_dom.
DR   InterPro; IPR014718; GH-type_carb-bd.
DR   Pfam; PF01263; Aldose_epim; 1.
DR   PIRSF; PIRSF005096; GALM; 1.
DR   SUPFAM; SSF74650; SSF74650; 1.
DR   PROSITE; PS00545; ALDOSE_1_EPIMERASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Carbohydrate metabolism; Cytoplasm;
KW   Disease variant; Isomerase; Phosphoprotein; Reference proteome.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   CHAIN           2..342
FT                   /note="Galactose mutarotase"
FT                   /id="PRO_0000197433"
FT   ACT_SITE        176
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000305|PubMed:15026423"
FT   ACT_SITE        307
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305|PubMed:15026423"
FT   BINDING         81..82
FT                   /ligand="beta-D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:27667"
FT                   /evidence="ECO:0000269|PubMed:15026423,
FT                   ECO:0007744|PDB:1SO0"
FT   BINDING         107
FT                   /ligand="beta-D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:27667"
FT                   /evidence="ECO:0000269|PubMed:15026423,
FT                   ECO:0007744|PDB:1SO0"
FT   BINDING         176..178
FT                   /ligand="beta-D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:27667"
FT                   /evidence="ECO:0000269|PubMed:15026423,
FT                   ECO:0007744|PDB:1SO0"
FT   BINDING         243
FT                   /ligand="beta-D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:27667"
FT                   /evidence="ECO:0000269|PubMed:15026423,
FT                   ECO:0007744|PDB:1SO0"
FT   BINDING         279
FT                   /ligand="beta-D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:27667"
FT                   /evidence="ECO:0000269|PubMed:15026423,
FT                   ECO:0007744|PDB:1SO0"
FT   BINDING         307
FT                   /ligand="beta-D-galactose"
FT                   /ligand_id="ChEBI:CHEBI:27667"
FT                   /evidence="ECO:0000269|PubMed:15026423,
FT                   ECO:0007744|PDB:1SO0"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         14
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         124
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q66HG4"
FT   VARIANT         82..342
FT                   /note="Missing (in GALAC4; loss of protein accumulation)"
FT                   /evidence="ECO:0000269|PubMed:30451973"
FT                   /id="VAR_083547"
FT   VARIANT         142
FT                   /note="G -> R (in GALAC4; unknown pathological
FT                   significance; decreased protein stability;
FT                   dbSNP:rs114440198)"
FT                   /evidence="ECO:0000269|PubMed:30451973"
FT                   /id="VAR_083548"
FT   VARIANT         190
FT                   /note="N -> Y (in dbSNP:rs6741892)"
FT                   /id="VAR_024451"
FT   VARIANT         267
FT                   /note="R -> G (in GALAC4; decreased protein stability)"
FT                   /evidence="ECO:0000269|PubMed:30451973"
FT                   /id="VAR_083549"
FT   VARIANT         311..342
FT                   /note="Missing (in GALAC4; decreased protein stability)"
FT                   /evidence="ECO:0000269|PubMed:30451973"
FT                   /id="VAR_083550"
FT   MUTAGEN         107
FT                   /note="H->A: Decreased activity by 5-fold."
FT                   /evidence="ECO:0000269|PubMed:12753898"
FT   MUTAGEN         176
FT                   /note="H->A: Decreased activity by 300-fold."
FT                   /evidence="ECO:0000269|PubMed:12753898"
FT   MUTAGEN         307
FT                   /note="E->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:12753898"
FT   STRAND          3..12
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   TURN            13..16
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          17..25
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          30..34
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          39..46
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          52..54
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   HELIX           62..66
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          81..83
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   HELIX           84..86
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          87..90
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          93..96
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          104..106
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          109..111
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   HELIX           113..115
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          119..123
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          126..133
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   HELIX           137..139
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          144..153
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          156..167
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          193..196
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          198..201
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   HELIX           230..236
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          243..248
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          251..253
FT                   /evidence="ECO:0007829|PDB:1SO0"
FT   STRAND          255..261
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   TURN            263..265
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          267..281
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          287..291
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   HELIX           293..295
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          297..299
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          304..310
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   HELIX           314..316
FT                   /evidence="ECO:0007829|PDB:1SNZ"
FT   STRAND          331..341
FT                   /evidence="ECO:0007829|PDB:1SNZ"
SQ   SEQUENCE   342 AA;  37766 MW;  611A54AE7E85813E CRC64;
     MASVTRAVFG ELPSGGGTVE KFQLQSDLLR VDIISWGCTI TALEVKDRQG RASDVVLGFA
     ELEGYLQKQP YFGAVIGRVA NRIAKGTFKV DGKEYHLAIN KEPNSLHGGV RGFDKVLWTP
     RVLSNGVQFS RISPDGEEGY PGELKVWVTY TLDGGELIVN YRAQASQATP VNLTNHSYFN
     LAGQASPNIN DHEVTIEADT YLPVDETLIP TGEVAPVQGT AFDLRKPVEL GKHLQDFHLN
     GFDHNFCLKG SKEKHFCARV HHAASGRVLE VYTTQPGVQF YTGNFLDGTL KGKNGAVYPK
     HSGFCLETQN WPDAVNQPRF PPVLLRPGEE YDHTTWFKFS VA
//
